Related references
Note: Only part of the references are listed.Does adjuvant vaccine therapy really have activity in malignant melanoma?
Keith Wheatley et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials
K. Wheatley et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
AMM Eggermont et al.
LANCET (2005)
A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma
JM Kirkwood et al.
CLINICAL CANCER RESEARCH (2004)
Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit?: A meta-analysis of the randomised trials
K Wheatley et al.
CANCER TREATMENT REVIEWS (2003)
Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
